About us
Biorepository and Research Laboratory
TOP > About us > Biorepository and Research Laboratory
The Biorepository and Research Laboratory supports clinical research through the processing, storage, and management of clinical specimens. We also design and perform experiments to develop clinical research in infectious diseases.
- Support for REBIND
(The REpository of Data and Biospecimen of INfectious Disease) project - Support and promote research on COVID-19
- Support and promote collaborative research with external organizations
Collaborating Institutions
- SB Coronavirus Inspection Center Corp.
- Abbott Japan LLC
- CANON MEDICAL SYSTEMS CORPORATION
- Sanyo Chemical Industries, Ltd.
Members
Update date: May 16, 2023
| Members | |
| Section chief | Moto KIMURA |
| Senior Researcher | Junko S. TAKEUCHI |
| Senior Researcher | Kento FUKANO |
| Technical Researcher | Azusa KAMIKAWA |
| Technical Assistant | Emiko HATANO |
| Administrative Assistant | Ryoko TAMURA |
| Research Student | Coco OKAMURA |
Achievements
Publications (since the start of the laboratory in 2021)
Publications (peer-reviewed journals)
-
[1] Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
S. Yamamoto, K. Matsuda, K. Maeda, K. Horii, K. Okudera, Y. Oshiro, N. Inamura, T. Nemoto, J. S. Takeuchi, Y. Li, M. Konishi, K. Tsuchiya, H. Gatanaga, S. Oka, T. Mizoue, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura and N. Ohmagari (2023).
J Infect Dis.
https://doi.org/10.1093/infdis/jiad317 -
[2] SARS-CoV-2 HaploGraph: visualization of SARS-CoV-2 haplotype spread in Japan.
S. Nakagawa, T. Katayama, L. Jin, J. Wu, K. Kryukov, R. Oyachi, J. S. Takeuchi, T. Fujisawa, S. Asano, M. Komatsu, J. I. Onami, T. Abe and M. Arita (2023).
Genes Genet Syst.
https://doi.org/10.1266/ggs.23-00085 -
[3] Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
Yamamoto, S., K. Matsuda, K. Maeda, Y. Oshiro, N. Inamura, T. Mizoue, M. Konishi, J. S. Takeuchi, K. Horii, M. Ozeki, H. Sugiyama, H. Mitsuya, W. Sugiura and N. Ohmagari (2023).
BMC Infect Dis 23(1): 282.
https://doi.org/10.1186/s12879-023-08272-2 -
[4] Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
Terada-Hirashima, J., Y. Takamatsu, Y. Shimizu, Y. Uemura, J. S. Takeuchi, N. Tomita, K. Matsuda, K. Maeda, S. Yamamoto, A. Fukunaga, N. Ohmagari, A. Mikami, K. Sonoda, M. Ujiie, H. Mitsuya and W. Sugiura (2023).
Hum Vaccin Immunother 19(1): 2193074.
https://doi.org/10.1080/21645515.2023.2193074. -
[5] Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-lambda3, CCL17, and calprotectin considering the timing of clinical need for prediction.
Yamamoto, K., Y. Ohsiro, T. Suzuki, M. Suzuki, S. Miura, M. Nagashima, N. Iwamoto, J. S. Takeuchi, M. Kimura, W. Sugiura, S. Nebuya, M. Kurokawa and N. Ohmagari (2023).
PLoS One 18(3): e0279897.
https://doi.org/10.1371/journal.pone.0279897. -
[6] Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan.
Li, Y., S. Yamamoto, Y. Oshiro, N. Inamura, T. Nemoto, K. Horii, J. S. Takeuchi, T. Mizoue, M. Konishi, M. Ozeki, H. Sugiyama, W. Sugiura and N. Ohmagari (2023).
J Hosp Infect 134: 97-107.
https://doi.org/10.1016/j.jhin.2023.01.018. -
[7] Neutralizing antibodies following three doses of BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron predominant wave.
Yamamoto, S., K. Matsuda, K. Maeda, K. Horii, K. Okudera, Y. Oshiro, N. Inamura, J. S. Takeuchi, M. Konishi, M. Ozeki, T. Mizoue, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari (2023).
Int J Infect Dis. 2023 Jan 21 : S1201-9712(23)00023-1.
https://doi.org/10.1016/j.ijid.2023.01.023. -
[8] SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study.
Takeuchi, J. S., A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, A. Kamikawa, Y. Kito, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, and W. Sugiura (2022).
Scientific Reports 12 (1): 15447.
https://doi.org/10.1038/s41598-022-19581-y -
[9] Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination.
Okumura, N., S. Saito, Y. Takamatsu, J. S. Takeuchi, Y. Asai, M. Sanada, N. Iwamoto, K. Maeda, H. Mitsuya, and N. Ohmagari (2022).
J Infect Chemother 28 (12): 1704-1706.
https://doi.org/10.1016/j.jiac.2022.08.026 -
[10] Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA).
Terayama, Y., N. Tomita, J. Terada-Hirashima, Y. Uemura, Y. Shimizu, J. S. Takeuchi, Y. Takamatsu, K. Maeda, A. Mikami, M. Ujiie, and W. Sugiura (2022).
Life (Basel) 12 (7).
https://doi.org/10.3390/life12070966 -
[11] Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
Okumura, N., S. Tsuzuki, S. Saito, S. I. Hattori, J. S. Takeuchi, T. Saito, M. Ujiie, M. Hojo, N. Iwamoto, W. Sugiura, H. Mitsuya, and N. Ohmagari (2022).
J Infect Chemother 28 (9): 1340-1343.
https://doi.org/10.1016/j.jiac.2022.04.018 -
[12] An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
Khor, S. S., Y. Omae, J. S. Takeuchi, A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, W. Sugiura, and K. Tokunaga (2022).
Vaccines (Basel) 10 (4).
https://doi.org/10.3390/vaccines10040563 -
[13] Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato, Y., K. Yamamoto, Y. Nakaya, S. Morioka, J. S. Takeuchi, Y. Takamatsu, K. Maeda, M. Kimura, W. Sugiura, H. Mitsuya, M. Yano, and N. Ohmagari (2022).
J Infect Chemother 28 (7): 991-994.
https://doi.org/10.1016/j.jiac.2022.03.002 -
[14] Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
Yamamoto, S., A. Fukunaga, A. Tanaka, J. S. Takeuchi, Y. Inoue, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, W. Sugiura, and N. Ohmagari (2022).
Vaccine 40 (13): 1924-1927.
https://doi.org/10.1016/j.vaccine.2022.02.052 -
[15] Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Yamamoto, S., K. Maeda, K. Matsuda, A. Tanaka, K. Horii, K. Okudera, J. S. Takeuchi, T. Mizoue, M. Konishi, M. Ozeki, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari (2022).
Clin Infect Dis 75 (1): e683-e691.
https://doi.org/10.1093/cid/ciab1048
Reviews in Japanese
-
[1] Current status and issues of drug-resistant HIV
Sugiura, W., J. S. Takeuchi, T.Kikuchi (2023).
Journal of clinical and experimental medicine (Igaku no ayumi) 284 (9) 657-661, 2023.
https://cir.nii.ac.jp/crid/1520576900032883328